Royalty Report: Drugs, Antibody, Disease – Collection: 243659

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Antibody
  • Disease
  • Therapeutic
  • Psoriasis
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 243659

License Grant
The Parties will focus their initial efforts on the development of Licensed Products to treat psoriasis.   In addition, the Parties shall develop Licensed Products for Organ Transplant Indications.

Licensor grants a worldwide license under the Licensor Patents and Licensor Know-How in the Field to develop, make, have made, use, sell, offer for sale, have sold and import Licensed Products. Such license shall be co-exclusive with Licensor in the Co-Promotion Territory and exclusive even as to Licensor in the  Licensee Territory.

License Property
Licensed Product or Licensed Products means a formulation for use in the Field containing Anti-CD11a or any molecule derived from Anti-CD11a that is substituted as the subject of this collaboration.

Anti-CD11a means that certain monoclonal antibody, and other constructs with minor modifications thereto resulting from changes to the manufacturing process occurring after the transfer thereof from Licensor to Licensee which is now known as Efalizumab, and which recognizes the CD11a cell adhesion molecule on leucocytes, the full length sequences of the light and heavy chains.

Field of Use
The Field means the use of Licensed Product for the treatment or prevention of any human condition, disorder or disease.  The Parties will focus their initial efforts on the development of Licensed Products to treat psoriasis.

'Initial Indications' means the use of Licensed Product for the treatment of psoriasis and the Organ Transplant Indication. For purposes of this Agreement, psoriasis is a single indication regardless of whether the psoriasis is mild, moderate or severe. Separate Initial Indications will not result based on the severity of the psoriasis or organ transplant rejection, the onset period of organ transplant rejection, or the demographics of the patient class.

Psoriasis is a long-lasting autoimmune disease characterized by patches of abnormal skin.

Anti-CD11a is an investigational, recombinant, humanized monoclonal antibody designed to prevent the activation of T-cells and their migration to sites of inflammation. The first Phase III randomized trial will involve approximately 30 sites throughout the United States and Canada for patients with moderate-to-severe plaque psoriasis. A second Phase III study is planned to begin in the first quarter 2000.

IPSCIO Record ID: 28354

License Grant
The Company entered into a collaborative agreement to jointly develop Xanelim(TM).
License Property
This is a co-development agreement for the humanized monoclonal antibody product Xanelim(TM).
Field of Use
Xanelim(TM) ids for treatment of psoriasis and organ transplant rejection.

IPSCIO Record ID: 260433

License Grant
The purpose of this agreement is to exclusively collaborate on the development of one or more products binding to and inhibiting the activity of GM-CSF.

The German Licensor grants to the German Licensee an exclusive license, with the right to grant sublicenses, to the Licensed Technology, other than the Sublicensed Patents and the Sublicensed Know-How, to conduct research and development, make, have made, use, Commercialize, and import the Products in the Field in the Territory.

Licensor grants an exclusive sublicense, with the right to grant further sublicenses, under the rights and licenses granted to Licensor in the Upstream Agreements with respect to the Sublicensed Technology, to research, develop, Commercialize, make, have made, use, offer for sale, sell, and import the Products in the Field in the Territory.

This agreement includes a non-exclusive grant beck from Licensee to Licensor.

License Property
Licensor is developing the MT203 Product, an anti-GM-CSF IgG1 antibody.

GM-CSF means the whole or part and natural variants of the granulocytemacrophage colony stimulating factor (GM-CSF) identified by the SWlSS-PROT entry name CSF2 _ HUMAN and accession number P04141 with the amino acid sequence as defined.

MT203 Product means any pharmaceutical product comprising the IgG1 antibody with the variable domain amino sequence.

The patents are for Antibody neutralizers of human granulocyte macrophage colony stimulating factor; and,  Method of identifying binding site domains that retain the capacity of binding to an epitope.

Field of Use
The Field means the treatment of human diseases and conditions.   The MT203 human antibody neutralizing the activity of granulocyte macrophage colony – stimulating factor (GM-CSF),  has potential applications in the treatment of inflammatory and autoimmune diseases.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.